Value of serum TXNIP and BIRC5 levels in clinical staging and efficacy monitoring in patients with primary laryngeal cancer
10.3969/j.issn.1673-4130.2024.10.021
- VernacularTitle:原发性喉癌患者血清TXNIP、BIRC5水平在临床分期判断及疗效监测中的价值
- Author:
Yuanyuan WEI
1
;
Lang XIONG
;
Lin ZHOU
Author Information
1. 鄂州市中心医院耳鼻喉科,湖北鄂州 436000
- Keywords:
primary laryngeal cancer;
thioredoxin-interacting protein;
baculoviral IAP repeat-contai-ning protein 5;
clinical staging;
efficacy prediction
- From:
International Journal of Laboratory Medicine
2024;45(10):1253-1256,1261
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the value of expression levels of serum thioredoxin-interacting protein(TXNIP)and baculoviral IAP repeat-containing protein 5(BIRC5)in clinical staging and efficacy monitoring in patients with primary laryngeal cancer(PLC).Methods From June 2020 to January 2023,a total of 68 pa-tients with PLC accepted by the hospital were collected as PLC group,and 80 patients with benign lesions were set as the benign tumors group.After six months of treatment,patients in the PLC group were separated into the treatment effective group(50 cases)and the treatment ineffective group(18 cases)according to the RECIST solid tumor efficacy evaluation criteria.Enzyme linked immunosorbent assay(ELISA)was applied to detect the levels of TXNIP and BIRC5 in serum of each group;the diagnostic efficacy of TXNIP and BIRC5 in staging PLC and the predictive efficacy of PLC patients were analyzed using the receiver operating characteris-tic(ROC)curve.Results There were statistically significant differences in the expression levels of TXNIP and BIRC5 in the serum between the PLC group and the benign tumors group(P＜0.05).The level of serum TXNIP in the treatment effective group[(99.52±14.12)pg/mL]was obviously higher than that in the treat-ment ineffective group[(85.19±15.17)μg/mL],and the difference was statistically significant(t=3.621,P＜0.05),while the BIRC5 expression level[(15.26±3.65)pg/mL]was obviously lower than that in the treatment ineffective group[(19.13±3.74)pg/mL],and the difference was statistically significant(t=3.833,P＜0.05).The serum TXNIP expression level in early PLC patients[(101.39±12.85)pg/mL]was obviously higher than that in late stage patients[(91.27±13.36)μg/mL],and the difference was statistically significant(t=3.154,P＜0.05),while the BIRC5 expression level[(14.43±3.07)pg/mL]was obviously lower than that in late stage patients[(17.74±3.04)pg/mL],and the difference was statistically significant(t=4.439,P＜0.05).The area under the curve(AUC)of serum TXNIP and BIRC5 in diagnosing PLC stag-ing was 0.829(95％CI:0.718-0.909)and 0.795(95％CI:0.679-0.883),respectively,with sensitivity of 81.58％and 89.47％,and the AUC of TXNIP combined BIRC5 in diagnosing PLC staging was 0.899(95％CI:0.802-0.959),with sensitivity of 94.74％.The AUC of serum TXNIP and BIRC5 in predicting the effi-cacy of PLC patients was 0.818(95％CI:0.705-0.901)and 0.761(95％CI:0.642-0.856),respectively,the AUC of the combination of the two was 0.921(95％CI:0.830-0.973),which had higher predictive efficiency(P＜0.05).Conclusion TXNIP is lowly expressed in the serum of patients with PLC,while BIRC5 is highly expressed in the serum of patients with PLC.The combination detection of TXNIP and BIRC5 has certain effi-cacy in the diagnosis of PLC staging and predicting the efficacy of PLC patients.
